This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Endoscopic Band Ligation (EBL) Versus Endoscopic Band Ligation and Propranolol for the Prevention of Variceal Rebleeding in Pts With Previous Variceal Treatment

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2009 by Korea University.
Recruitment status was:  Recruiting
Information provided by:
Korea University Identifier:
First received: August 25, 2009
Last updated: NA
Last verified: August 2009
History: No changes posted
Both propranolol and endoscopic band ligation (EBL) are effective for prevention of variceal rebleeding. Recently several studies compared the efficacy of EBL alone and with a combination of propranolol and EBL. However, the results of recent studies showed discrepancy. In addition, most of all recent studies included patients without previous endoscopic treatment for varices. This study is performed to compare the efficacy and safety of EBL alone and EBL combined with propranolol in patients who were previously performed endoscopic variceal treatment.

Condition Intervention Phase
Cirrhosis Variceal Bleeding Procedure: endoscopic band ligation Procedure: Endoscopic band ligation and propranolol Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: RCT Comparing the Efficacies of Endoscopic Band Ligation (EBL) and Combined Treatment of Beta-blocker and EBL for the Prevention of Esophageal Variceal Rebleeding in Patients With Previous Endoscopic Variceal Treatment

Resource links provided by NLM:

Further study details as provided by Korea University:

Primary Outcome Measures:
  • Rebleeding from esophageal varices [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Upper gastrointestinal bleeding; Significant esophageal variceal bleeding; Mortality; Adverse events [ Time Frame: 2 years ]

Estimated Enrollment: 180
Study Start Date: August 2008
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Endoscopic band ligation
Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval
Procedure: endoscopic band ligation
Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
Active Comparator: EBL+Propranolol
Procedure: Endoscopic band ligation and propranolol

Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval

Active Comparator: EBL+Propranolol Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Liver cirrhosis
  • Age between 18 and 70 years
  • Successful control of esophageal variceal bleeding within 6 weeks before enrollment

Exclusion Criteria:

  • Gastric variceal bleeding
  • Patients with systolic blood pressure <100 mmHg or basal heart rate <60/min
  • Portal vein thrombosis
  • Prominent hepatic encephalopathy
  • Coexisting untreated malignancy
  • Severe cerebrovascular or cardiovascular disease, renal failure
  • No previous history of endoscopic, radiologic, or surgical treatment for varices or ascites
  • Contraindication to beta-blocker
  • Pregnancy
  • Refusal to give consent to participate in the trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00966082

Contact: Soon Ho Um, Prof 82-2-920-5019
Contact: Yeon Seok Seo, MD 82-2-920-6608

Korea, Republic of
Korea University Anam Hospital Recruiting
Seoul, Korea, Republic of, 136-705
Sponsors and Collaborators
Korea University
  More Information

Responsible Party: Liver Cirrhosis Clinical Research Center, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Anam Hospital Identifier: NCT00966082     History of Changes
Other Study ID Numbers: EBLPPL-2
Study First Received: August 25, 2009
Last Updated: August 25, 2009

Keywords provided by Korea University:
Esophagus Disorders
Varicose Veins

Additional relevant MeSH terms:
Pathologic Processes
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Vasodilator Agents processed this record on August 18, 2017